Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

[Treatment progress for EGFR wild-type advanced non-small cell lung cancer].

Ma F, Shi X, Meng W, Zhang J, Zhao L, He X, Zhao J.

Zhongguo Fei Ai Za Zhi. 2014 Jul 20;17(7):575-80. doi: 10.3779/j.issn.1009-3419.2014.07.14. Review. Chinese.

2.

[Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?].

Liu X, Xu J.

Zhongguo Fei Ai Za Zhi. 2014 Oct 20;17(10):709-14. doi: 10.3779/j.issn.1009-3419.2014.10.01. Review. Chinese.

3.

[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].

Li X, Zhu G.

Zhongguo Fei Ai Za Zhi. 2014 Apr;17(4):357-62. doi: 10.3779/j.issn.1009-3419.2014.04.12. Review. Chinese.

4.
5.

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.

Tam TC, Ho JC, Wong MK, Wong WM, Wang JK, Lam JC, Lui MM, Lam WK, Ip MS, Lam DC.

Lung. 2013 Dec;191(6):645-54. doi: 10.1007/s00408-013-9498-9.

6.
7.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.

J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Erratum in: J Clin Oncol. 2015 Jun 20;33(18):2124.

PMID:
22215752
9.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016.

PMID:
24768581
10.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357.

11.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.

Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.

PMID:
22082647
12.

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Wu WS, Chen YM, Tsai CM, Shih JF, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2013 Dec;76(12):682-5. doi: 10.1016/j.jcma.2013.08.006.

13.

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.

Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciadiello F, Gridelli C.

Curr Med Chem. 2012;19(20):3337-52. Review.

PMID:
22664249
14.

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Chen YM.

J Chin Med Assoc. 2013 May;76(5):249-57. doi: 10.1016/j.jcma.2013.01.010. Review.

15.

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Tartarone A, Lerose R, Lazzari C, Gregorc V, Aieta M.

Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Review.

PMID:
24958518
16.

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y.

Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364.

17.

[EGFR mutations in patients with advanced NSCLC].

Fiala O, Pešek M, Fínek J, Brůha F, Bortlíček Z, Krejčí J, Benešová L, Minárik M.

Klin Onkol. 2012;25(4):267-73. Czech.

PMID:
22920167
18.

Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, Chen JX, Shen XH.

J Integr Med. 2014 Jul;12(4):346-58. doi: 10.1016/S2095-4964(14)60034-0. Review.

PMID:
25074884
19.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.

Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Review.

PMID:
24486058

Supplemental Content

Support Center